The FDA has extended its review of Eisai and Biogen's new subcutaneous formulation of Alzheimer's disease therapy Leqembi – ...

Longevity investment went from $3.8bn in 2023 to $8.5bn in 2024 (albeit in the context of a broader biotech market recovery).

Swiss biotech Windward Bio is planning to take on some heavyweight rivals with its TSLP-acting drug for inflammatory respiratory and dermatological diseases – a mission that will be helped by adding ...

The Pharma Specialized Network (PSN) provides a globally integrated solution for delivering end-to-end distribution to ...

The evolving role of early-phase clinical trials reflects a broader truth: decisions made early carry increasing weight in ...

To understand the key trends and client conversations that shaped this year's summit, pharmaphorum sat down with Krista Pinto ...

Across events and general day-to-day industry updates, one term has dominated market access conversations in 2026: Most ...

Radiotracer-enhanced PET/CT scan, showing positive uptake in the heart of patient with cardiac amyloidosis. Armed with new phase 3 data, Bayer is preparing to file for approval of a new PET imaging ...

Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy (GA), a complication of age-related macular degeneration (AMD), as it prepares to test it in a clinical ...

Roche has been working with US AI specialist PathAI for around five years, and has now upgraded that partnership with an offer to buy the company outright for $1.05 billion. Already a giant in the ...

Digital pathology specialist Paige has been awarded breakthrough device status from the FDA for an artificial intelligence tool that can be used to detect cancer across different areas of the body.

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, targeted treatment for non-small cell lung cancer (NSCLC). The German pharma ...